1. Asosingh K, de Raeve H, de Ridder M, Storme GA, Willems A, van Riet I, van Camp B, Vanderkerken K (2005) Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 90 (6): 810–817.
2. Borsi E, Perrone G, Terragna C, Martello M, Dico AF, Solaini G, Baracca A, Sgarbi G, Pasquinelli G, Valente S, Zamagni E, Tacchetti P, Martinelli G, Cavo M (2014) Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. Oncotarget 5 (7): 1779–1792.
3. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L, Ravanetti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A, Greco A, Mangoni M, Bonati A, Rizzoli V, Giuliani N (2007) The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 110 (13): 4464–4475.
4. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr ., Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Mohler T, Rossi JF, Jauch A, Klein B, Goldschmidt H (2011) Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 96 (1): 87–95.
5. Hose D, Seckinger A, Goldschmidt H, Meissner T, Leber B, Neben K, Hillengass J, Bertsch U, Janssen B, Klein B, Lewis J, Vanderkerken K, Schultes C (2010) A novel class of sulfonanilides entering clinical trials for targeted treatment of multiple myeloma: dual-mechanism compounds inhibiting hif1a-signaling and inducing apoptosis. ASH Annual Meeting Abstracts 116 (21): 2987.